IVIG for Drug and Device Refractory Gastrointestinal Auto-Immune Neuropathy

Recruiting now

Conditions studied: Gastrointestinal Motility Disorder, Gastroparesis, Neuropathy

In brief

Patients with the symptoms of generalized GI dysmotility, including gastroparesis, are sometimes refractory to available medications, devices and other interventions/ Some of these patients have serologic and/or endo organ abnormalities and findings consistent with autoimmune neuropathies, primarily involving the GI tract. These disorders have been known as autoimmune gastrointestinal neuropathies (GAIN) or also as autoimmune gastrointestinal dysmotility (AGID), among other terms. Some patients respond to intravenous immunoglobulin (IVIG) and this study, which is an observational clinical series, documents the patients, their findings and standardized responses to therapy with IVIG.

Key facts

Study ID
NCT04208828
Run by
University of Louisville
People needed
400
Starts
2020-01-02
Expected to finish
2028-01-02
Last updated by the study team
2025-08-01

Who can join

Age: 12 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.